ADB COMBINATION FOR USE IN HCV TREATMENT

摘要

AAD combination for use in treating HCV. # The present invention provides combinations of antiviral agents for use in therapy without interferon and ribavirin in the treatment of HCV. Preferably the treatment is for a short treatment time, such as no more than 12 weeks. In one aspect, the use of combinations of antiviral agents in therapy comprises administering at least two direct-acting antiviral agents without interferon and ribavirin to a subject with HCV infection.